Interventions in the House of Commons
RSS feed based on search criteria Export search results - CSV (plain text) Export search results - XML
Add search criteria
View Gord Johns Profile
View Gord Johns Profile
2019-06-19 21:04 [p.29438]
Mr. Speaker, we have some concerns around this trade agreement, especially when it comes to biologic medicines that are the most expensive and profitable class of medicines out there. For example, popular biologics to treat rheumatic arthritis and Crohn's disease can cost between $20,000 and $30,000 annually. The cost for certain biologics designed to treat rare diseases can be substantially higher. Biosimilars can significantly lower these costs, increasing access and stretching heath dollars further. Even insulin costs are going up.
Why does the government want Canadians suffering from these types of illnesses to have to pay more for their medications? That is what is going to happen if this trade agreement is ratified as it is.
Result: 1 - 1 of 1